Drugs / PCAR-119
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02892695 | Sep 2016 → Sep 2018 | B-cell prolymphocytic leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, diffuse large B-cell lymphoma, follicular lymphoma +1 | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PCAR-119 | “PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma” NCT02892695 ↗ |
| Action | Deplete | “are able to kill leukemia blasts” PMID 28054442 ↗ Feb 2017 |
| Modality | Cell therapy | “CAR-NK cell immunotherapy” NCT02892695 ↗ |
| Route | Other | “by infusion” NCT02892695 ↗ |
| Target | CD19 | “targeting CD19 antigen” NCT02892695 ↗ |